Napo eu s.p.a., jaguar health's italian subsidiary, and dragon spac s.p.a.

Napo eu, the identified target of dragon spac, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the us fda for sbs) merger of napo eu & dragon spac expected to be effective within approximately 80 days, with related future sbs license and milestone fees totaling up to $12.5 million milan, italy and san francisco, ca / accesswire / july 19, 2021 / dragon spac s.p.a. and napo eu s.p.a.
JAGX Ratings Summary
JAGX Quant Ranking